Jaypirca peak sales estimate?

What are peak sales estimates for Jaypirca?

Jaypirca is a multiple myeloma treatment developed by Bristol Myers Squibb (BMS). As of my knowledge cutoff, BMS had not disclosed exact peak sales estimates for the medication. However, analysts have made some projections based on the drug's potential market share and pricing.

How does Jaypirca's market potential compare to existing treatments?

Jaypirca is a next-generation myeloma treatment that targets the myeloma tumor microenvironment. Analysts believe that Jaypirca could capture a significant portion of the growing myeloma treatment market, potentially competing with established treatments like AbbVie's Venclexta and Pfizer's Revlimid [1].

What are the factors influencing Jaypirca's sales potential?

Several factors are likely to influence Jaypirca's sales potential, including its pricing, market share, and reimbursement status. Analysts have noted that BMS has set a list price for Jaypirca that is slightly lower than the list price for Venclexta, which could help the medication gain market traction [2].

When will Jaypirca patent exclusivity expire?

According to DrugPatentWatch.com, the patent exclusivity for Jaypirca is set to expire in 2036, assuming the medication is approved and launched as expected [3]. After patent expirations, biosimilars may enter the market, potentially impacting sales of the original medication.

References

[1] www.abbvie.com - Venclexta product information
[2] www.pfizer.com - Revlimid product information
[3] DrugPatentWatch.com - Jaypirca patent information